Articles by Heme Today Staff Writers
This would be the fourth authorized indication for luspatercept in the European Union.
A pooled study showed treatment with ruxolitinib achieved durable hematocrit control.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.